56946-83-9

Usage

Uses

Used in Pharmaceutical Industry:
2,5-Dichlorothiophene-3-sulfonyl chloride is used as a synthetic intermediate for the preparation of various pharmaceutical compounds. Its application is primarily due to its ability to react with other molecules to form new compounds with potential therapeutic properties.
Used in the Synthesis of Specific Compounds:
1. 2,5-Dichlorothiophene-3-sulfonyl chloride is used as a key intermediate for the synthesis of 1-[(2,5-dichloro-3-thienyl)sulfonyl]-N-(6-nitro-1,3-benzothiazol-2-yl)piperidine-4-carboxamide. 2,5-Dichlorothiophene-3-sulfonyl chloride may have potential applications in the development of new drugs targeting specific medical conditions.
2. It is also utilized in the preparation of 6-chloro-3-isopropylamino-4H-thieno[2,3-e]-1,2,4-thiadiazine 1,1-dioxide, which is another compound that could be explored for its pharmaceutical potential.
3. Additionally, 2,5-Dichlorothiophene-3-sulfonyl chloride is used in the synthesis of 6-fluoro-3-methyl-4-(2,5-dichlorothiophene-3-sulfonyl)-3,4-dihydroquinoxalin-2-(1H)-one, a compound that may have potential applications in the field of medicinal chemistry.

InChI:InChI=1/C4HCl3O2S2/c5-3-1-2(4(6)10-3)11(7,8)9/h1H

Upstream product

• 3172-52-9 2,5-diclorothiophene 

Downstream Products

• 59768-12-6 2,5-dichloro-4-nitrothiophene-3-sulfonyl Chloride 
• 1096925-38-0 4-{[(2,5-dichlorothiophen-3-yl)sulfonyl]amino}-2-hydroxybenzoic acid 
• 1448334-90-4 1-(2,5-dichloro-thiophene-3-sulfonyl)-4-[5-(4-methoxyphenyl)-[1,3,4]oxadiazol-2-yl]piperazine 
• 53595-68-9 2,5-dichloro-3-thiophenesulfonamide 
• 1365699-65-5 4β-[2,5-dichlorothiophene-3-sulfonamido]podophyllotoxin 

Relevant academic research and scientific papers

2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE

The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain 2-amino-N-(amino-oxo-aryl-λ6- sulfanylidene)acetamide compounds (referred to herein as ANASIA compounds) that, inter alia, inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase (aaRS) (e.g., bacterial leucyl-tRNA synthetase, LeuRS). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit (e.g., selectively inhibit) bacterial aminoacyl-tRNA synthetase; to treat disorders that are ameliorated by the inhibition (e.g., selective inhibition) of bacterial aminoacyl-tRNA synthetase; to treat bacterial infections; etc.

Concise synthesis and displacement reactions of model 3-(alkylthio)- 6-chloro- and 2,6-dichlorothieno[2,3-e][1,4,2]dithiazine 1,1-dioxides

A series of 3-(alkylthio)-6-chlorothieno[2,3-e][1,4,2]dithiazine 1,1-dioxides (7a - e) were prepared via interaction of deprotonated 2,5-dichlorothiophene-3-sulfonamide with carbon disulfide under reflux, followed by alkylation with alkyl halides. Employment of dimethyl sulfate afforded the isomeric 2-methyl-3-thione derivative 8 together with the expected 3-(methylthio) derivative 7ain a molar ratio of 1 : 4. Treatment of 7a or 10 with ethylamine, aniline or p-chloroaniline produced the corresponding N-ethyl- (or N-phenyl)-6-chlorothieno[2,3-e][1,4,2]dithiazine-3-amine 1,1-dioxides 3a - c. Likewise, interaction of 7a with methylhydrazine (or phenylhydrazine) gave the respective 3-(1-methylhydrazinyl or 2-phenylhydrazinyl) 1,1-dioxides9a, b. Desulfonation of 6-chloro-3-(methylthio)thieno[ 2,3-e][1,4,2]dithiazine 1,1-dioxide (7a) with sulfuryl chloride produced 3,6-dichlorothieno[2,3- e][1,4,2]dithiazine 1,1-dioxide (10). The latter compound was used as a substrate for the preparation of N-alkyl- (or aryl)-6-chlorothieno[2,3-e][1,4,2] dithiazin-3-amine 1,1-dioxides 3a - c representing a new approach for the synthesis of similar derivatives. Compounds 7a -e showed modest to low antibacterial activity against E. coli and S. aureus.

Phenylenediamine urotensin-II receptor antagonists and CCR-9 antagonists

The present invention relates to urotensin II receptor antagonists, CCR-9 antagonists, pharmaceutical compositions containing them and their use.

Effect of structural modification of enol-carboxamide-type nonsteroidal antiinflammatory drugs on COX-2/COX-1 selectivity

Meloxicam (5), an NSAID in the enol-carboxamide class, was developed on the basis of its antiinflammatory activity and relative safety in animal models. In subsequent screening in microsomal assays using human COX-1 and COX-2, we discovered that it possessed a selectivity profile for COX-2 superior to piroxicam and other marketed NSAIDs. We therefore embarked on a study of enol-carboxamide type compounds to determine if COX-2 selectivity and potency could be dramatically improved by structural modification. Substitution at the 6- and 7-positions of the 4-oxo-1,2-benzothiazine-3- carboxamide, alteration of the N-methyl substituent, and amide modification were all examined. In addition we explored several related systems including the isomeric 3-oxo-1,2-benzothiazine-4-carboxamides, thienothiazines, indolothiazines, benzothienothiazines, naphthothiazines, and 1,3- and 1,4- dioxoisoquinolines. While a few examples were found with greater potency in the COX-2 assay, no compound tested had a better COX-2/COX-1 selectivity profile than that of 5.

Fungicidal sulfonamidothiophenes

Novel thiophenes of the formula STR1 wherein X and Z individually are nitro, fluoro, chloro or bromo, Y is hydrogen, nitro, fluoro, chloro or bromo, R1 is alkyl or aryl and R2 is hydrogen or haloalkylthio, are useful for the prevention or cure of fungal infections.

Fungicidal 5-dialkylamino-4-nitrosulfonamidothiophenes

Novel thiophenes of the formula STR1 wherein R1 is alkyl; R2 is alkyl; one X is hydrogen, fluoro, chloro or bromo and the other X is --SC2 N(R3)(R4) wherein R3 is alkyl or aryl and R4 is hydrogen or haloalkylthio, are useful for the prevention or cure of fungal infections.